Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Nicola Nicolai , MariaFrancesca Alvisi , Tiziana Rancati , Barbara Avuzzi , Fabio Badenchini , Mario Catanzaro , Maurizio Colecchia , Teresa Di Florio , Tiziana Magnani , Cristina Marenghi , Sara Morlino , Barbara Noris Chiorda , Biagio Paolini , Silvia Stagni , Antonio Tesone , Tullio Torelli , Sergio Villa , Nadia Zaffaroni , Roberto Salvioni , Riccardo Valdagni
Background: Prostate biopsy findings at diagnosis and follow-up are essential criteria in Active Surveillance (AS). In a previous work (Nicolai Eur Urol Suppl 2013) upgrading (UPG) and upsizing (UPS) at 1-yr rebiopsy resulted to be independent outcomes with different predictors. Aim of the present work is to validate these models on an independent population and to evaluate the probability of not-developing UPG, thus the chance of continuing AS Methods: Pts enrolled in 2011-2017 were considered for validation, while 318 AS pts enrolled in 2005-2011 were considered for model development. UPG model included: age (risk), PSA density (risk), prostate volume (>60 cc, protective); UPS model: age (protective), % core length containing cancer (>5%, risk), number of positive cores (>1, risk) Performance on the independent population was evaluated through AUC and calibration. Logistic model for not-developing UPG at 1 yr was fitted using all available AS pts Results: 433 pts were included in the validation set. UPG and UPS were registered in 43 and 29 pts, respectively; 38 pts had UPG+UPS. Predictors for UPG and UPS were mainly confirmed in the validation cohort (Table), with Odds Ratios (OR) very similar to the development model. Discrimination was confirmed (AUCs) and calibration was excellent (slope~1, R2>0.90). Probability of not-developing UPG (evaluated on 751 pts) was associated to age, prostate volume and PSA density (Table). Conclusions: UPG and UPS in AS pts should be considered as independent events and their management implying different strategies. Specifically, age, volume and PSA density play a key role in the chance to continue AS, i.e. in not developing UPG. A nomogram estimating the likelihood of continuing AS has been developed and will be presented.
Upgrading | DEVELOPMENT (n=318) | VALIDATION (n=433) | ||||
---|---|---|---|---|---|---|
OR | p | AUC | OR | p | AUC | |
Age (continuous) | 1.06 | 0.04 | 0.60 | 1.09 | 0.001 | 0.72 |
Prostate volume >60 cc | 0.2 | 0.03 | 0.4 | 0.04 | ||
PSA density (continuous) | 1.02 | 0.3 | 1.05 | 0.01 | ||
Upsizing | OR | p | AUC | OR | p | AUC |
Age (continuous) | 0.97 | 0.29 | 0.63 | 1.0 | 0.88 | 0.66 |
>5% core involvement | 2.9 | 0.04 | 1.3 | 0.35 | ||
>1 positive cores | 1.6 | 0.29 | 3.0 | 0.0 | ||
NO UPGRADING (n=751) | OR | p | AUC | |||
Age (continuous) | 0.94 | <0.0001 | ||||
Prostate volume >60 cc | 2.65 | <0.0001 | 0.69 | |||
PSA density (continuous) | 0.96 | 0.004 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Takuma Kato
2024 ASCO Genitourinary Cancers Symposium
First Author: Lauren Lenz
2023 ASCO Annual Meeting
First Author: Gwenaelle Gravis
2021 Genitourinary Cancers Symposium
First Author: Takuma Kato